Diabetes action Canada annual workshop Friday MAY 31 2019 Bruce A Perkins Leif E Lovblom Nancy Cardinez Andrej Orszag Marcelo Falappa Devrim Eldelekli Daniel Scarr Ahmad Haidar ID: 1037864
Download Presentation The PPT/PDF document "Does Sodium Linked Transporter (SGLT) In..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Does Sodium Linked Transporter (SGLT) Inhibition Improve Performance of the Artificial Pancreas in Type 1 Diabetes? Diabetes action Canada annual workshopFriday, MAY 31, 2019 Bruce A. Perkins, Leif E. Lovblom, Nancy Cardinez, Andrej Orszag,Marcelo Falappa, Devrim Eldelekli, Daniel Scarr, Ahmad Haidar Bruce A. Perkins MD MPHProfessor and Clinician-ScientistSam and Judy Pencer Family Chair in Diabetes Clinical ResearchLeadership Sinai Centre for DiabetesDivision of Endocrinology
2. Does Sodium Linked Transporter (SGLT) Inhibition Improve Performance of the Artificial Pancreas in Type 1 Diabetes?Study purpose: We aimed to determine if Empagliflozin (EMPA) can improve the performance of the artificial pancreas and reduce carbohydrate counting burden from patients.Current artificial pancreas algorithms regulate blood sugars during the night time but not very well following meals Sodium Glucose-Linked Transporter inhibitors (SGLTi) like EMPA lower blood glucose through elimination of sugar in the urine and may help the artificial pancreas algorithm work better with meals Artificial Pancreas (AP)Trial Design:We are currently doing a randomized placebo-controlled trial of EMPA in people living with T1D using the McGill Artificial Pancreas algorithm, and we have preliminary results on 16 people
3. Does Sodium Linked Transporter (SGLT) Inhibition Improve Performance of the Artificial Pancreas in Type 1 Diabetes?Preliminary results suggest that SGLT inhibition added to the Artificial Pancreas substantially improved glucose control, can reduce patients’ need for burdensome carbohydrate counting and appears safe.TIR= Time in Range (3.9-10.0 mmol/l